However, several promising nonpeptide, vasopressin receptor antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463.

Oral administration of the vasopressin V2-receptor antagonist tolvaptan is safe and effective for the treatment of chronic hyponatremia in the long term, according to the results of the SALTWATER ...

Researchers from Gedeon Richter plc have reported the discovery of novel dual vasopressin V1A/V2 antagonist, drug candidates for arginine vasopressin (AVP) for the potential treatment of hyponatremia.

Many studies have focused on the role of arginine vasopressin (AVP ... repeated intracerebroventricular (i.c.v.) injections of antagonists to the AVP-V1a receptor (AVPR) or of antagonists to ...

Tolvaptan is a vasopressin receptor antagonist. Vasopressin (a.k.a. ADH or antidiuretic hormone) helps to regulate water retention by absorbing water in the collecting ducts of the nephron.

Drug therapy of AHFS may include diuretics, vasodilators, morphine, ACE inhibitors, digoxin, inotropes, and vasopressin antagonists. Clinical practice guidelines for patients with AHFS provide a ...

If blood pressure suddenly drops, vasopressin released by the pituitary gland will attach to receptors on the outside of blood vessels (called V1a receptors), causing vasoconstriction. By ...

HMNC Brain Health (HMNC) has completed the subject randomisation in its placebo-controlled Phase IIb OLIVE trial of a vasopressin V1b receptor antagonist, BH-200, for major depressive disorder ...

The drug is a vasopressin 1a (V1a) receptor antagonist, and evidence from human and animal studies suggest that the V1a receptor has a role in mediating and modulating key social behaviours ...

The trial is investigating the efficacy and safety of BH-200, a potent vasopressin V1b receptor antagonist, alongside a predictive companion diagnostic in patients with Major Depressive Disorder (MDD) ...